Overview

Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to find optimum dosage of DW-3101 by evaluating efficacy and safety of each dosage group in Korean patients with acute and chronic gastric inflammation.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Criteria
Inclusion Criteria:

- Adult males/females aged 20~75 years

- Patients detected over 1 erosion who diagnosed as acute or chronic gastric
inflammation by gastrscopy in 7days before administration of experimental agents

- Subjects who voluntarily agree to participate in this clinical test with written
consent

Exclusion Criteria:

- Patients impossible gastroscopy

- In case accompanied with gastric ulcer(scar excepted) or reflux esophagitis

- Patients who had stomach or esophagus surgery to inhibit gastric acid secretion
(tresis or appendicectomy surgery excluded)

- Patients with malignant tumor on digestive organ

- Patients with blood clot(cerebral thrombosis, myocardial infarction, septic
thrombophlebitis) and who have antithrombotic agents (eg. warfarin)